The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Cobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma
Open accessAbstract
Summary: miR‐155, a microRNA associated with poor prognosis in lymphoma and leukaemia, has been implicated in the progression of mycosis fungoides (MF), the most common form of cutaneous T‐cell lymphoma (CTCL). In this study, we developed and tested cobomarsen (MRG‐106), a locked nucleic acid‐modified oligonucleotide inhibitor of miR‐155. In MF and human lymphotropic virus type 1 (HTLV‐1+) CTCL cell lines in vitro, inhibition of miR‐155 with cobomarsen de‐repressed direct miR‐155 targets, decreased expression of multiple gene pathways associated with cell survival, reduced survival signalling, decreased cell proliferation and activated apoptosis. We identified a set of genes that are significantly regulated by cobomarsen, including direct and downstream targets of miR‐155. Using clinical biopsies from MF patients, we demonstrated that expression of these pharmacodynamic biomarkers is dysregulated in MF and associated with miR‐155 expression level and MF lesion severity. Further, we demonstrated that miR‐155 simultaneously regulates multiple parallel survival pathways (including JAK/STAT, MAPK/ERK and PI3K/AKT) previously associated with the pathogenesis of MF, and that these survival pathways are inhibited by cobomarsen in vitro. A first‐in‐human phase 1 clinical trial of cobomarsen in patients with CTCL is currently underway, in which the panel of proposed biomarkers will be leveraged to assess pharmacodynamic response to cobomarsen therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043
MicroRNA biogenesis pathways in cancer
Lin, S., & Gregory, R. I. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3932 · Cited by 2,112
Accumulation of miR-155 and BIC RNA in human B cell lymphomas
Eis, P. S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M. F., Lund, E., & Dahlberg, J. E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500613102 · Cited by 1,325
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice
Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N., & Croce, C. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602266103 · Cited by 951
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826
Identification of Drosophila MicroRNA Targets
Stark, A., Brennecke, J., Russell, R. B., & Cohen, S. M. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000060 · Cited by 784
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 768
O'Connell, R. M., Rao, D. S., Chaudhuri, A. A., Boldin, M. P., Taganov, K. D., Nicoll, J., Paquette, R. L., & Baltimore, D. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072108 · Cited by 681
Kluiver, J., Poppema, S., de Jong, D., Blokzijl, T., Harms, G., Jacobs, S., Kroesen, B., & van den Berg, A. (2005) · The Journal of Pathology · doi:10.1002/path.1825 · Cited by 672
Ceppi, M., Pereira, P. M., Dunand-Sauthier, I., Barras, E., Reith, W., Santos, M. A., & Pierre, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811073106 · Cited by 631
Transcripts Targeted by the MicroRNA-16 Family Cooperatively Regulate Cell Cycle Progression
Linsley, P. S., Schelter, J., Burchard, J., Kibukawa, M., Martin, M. M., Bartz, S. R., Johnson, J. M., Cummins, J. M., Raymond, C. K., Dai, H., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02005-06 · Cited by 552
Self-citationHigh expression of precursor microRNA‐155/BIC RNA in children with Burkitt lymphoma
Metzler, M., Wilda, M., Busch, K., Viehmann, S., & Borkhardt, A. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10316 · Cited by 543
Ma, X., Becker Buscaglia, L. E., Barker, J. R., & Li, Y. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr007 · Cited by 542
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Babar, I. A., Cheng, C. J., Booth, C. J., Liang, X., Weidhaas, J. B., Saltzman, W. M., & Slack, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201516109 · Cited by 497
microRNA Target Predictions across Seven Drosophila Species and Comparison to Mammalian Targets
Grün, D., Wang, Y.-L., Langenberger, D., Gunsalus, K. C., & Rajewsky, N. (2005) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0010013 · Cited by 446
Kaposi's Sarcoma-Associated Herpesvirus Encodes an Ortholog of miR-155
Skalsky, R. L., Samols, M. A., Plaisance, K. B., Boss, I. W., Riva, A., Lopez, M. C., Baker, H. V., & Renne, R. (2007) · Journal of Virology · doi:10.1128/jvi.01804-07 · Cited by 445
Modulation of mismatch repair and genomic stability by miR-155
Valeri, N., Gasparini, P., Fabbri, M., Braconi, C., Veronese, A., Lovat, F., Adair, B., Vannini, I., Fanini, F., Bottoni, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002472107 · Cited by 349
MicroRNA and cancer – focus on apoptosis
Wang, Y., & Lee, C. G. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00510.x · Cited by 330
Wang, L., Ni, X., Covington, K. R., Yang, B. Y., Shiu, J., Zhang, X., Xi, L., Meng, Q., Langridge, T., Drummond, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3444 · Cited by 323
Self-citationTranscriptome-wide miR-155 Binding Map Reveals Widespread Noncanonical MicroRNA Targeting
Loeb, G. B., Khan, A. A., Canner, D., Hiatt, J. B., Shendure, J., Darnell, R. B., Leslie, C. S., & Rudensky, A. Y. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.10.002 · Cited by 311
Willemze, R., Hodak, E., Zinzani, P. L., Specht, L., & Ladetto, M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt242 · Cited by 296
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)
Ralfkiaer, U., Hagedorn, P. H., Bangsgaard, N., Løvendorf, M. B., Ahler, C. B., Svensson, L., Kopp, K. L., Vennegaard, M. T., Lauenborg, B., Zibert, J. R., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358382 · Cited by 240
B-cell Receptor Activation Induces BIC/miR-155 Expression through a Conserved AP-1 Element
Yin, Q., Wang, X., McBride, J., Fewell, C., & Flemington, E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708218200 · Cited by 232
Mutator activity induced by microRNA-155 ( miR-155 ) links inflammation and cancer
Tili, E., Michaille, J.-J., Wernicke, D., Alder, H., Costinean, S., Volinia, S., & Croce, C. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101795108 · Cited by 227
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
So, L., & Fruman, D. A. (2012) · Biochemical Journal · doi:10.1042/bj20112092 · Cited by 218
Yamanaka, Y., Tagawa, H., Takahashi, N., Watanabe, A., Guo, Y.-M., Iwamoto, K., Yamashita, J., Saitoh, H., Kameoka, Y., Shimizu, N., et al. (2009) · Blood · doi:10.1182/blood-2009-06-222794 · Cited by 209
Onco‐miR‐155 targets SHIP1 to promote TNFα‐dependent growth of B cell lymphomas
Pedersen, I. M., Otero, D., Kao, E., Miletic, A. V., Hother, C., Ralfkiaer, E., Rickert, R. C., Gronbaek, K., & David, M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900028 · Cited by 209
Zhang, C., Hazarika, P., Ni, X., Weidner, D. A., & Duvic, M. A. (2002) · PubMed · Cited by 201
Self-citationEscobar, T. M., Kanellopoulou, C., Kugler, D. G., Kilaru, G., Nguyen, C. K., Nagarajan, V., Bhairavabhotla, R. K., Northrup, D., Zahr, R., Burr, P., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.014 · Cited by 183
Sors, A., Jean-Louis, F., Pellet, C., Laroche, L., Dubertret, L., Courtois, G., Bachelez, H., & Michel, L. (2006) · Blood · doi:10.1182/blood-2005-06-2536 · Cited by 174
Mutant p53 drives invasion in breast tumors through up-regulation of miR-155
Neilsen, P. M., Noll, J. E., Mattiske, S., Bracken, C. P., Gregory, P. A., Schulz, R. B., Lim, S. P., Kumar, R., Suetani, R. J., Goodall, G. J., et al. (2013) · Oncogene · doi:10.1038/onc.2012.305 · Cited by 167
STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma
Kopp, K., Ralfkiær, U., Gjerdrum, L. M. R., Helvad, R., Pedersen, I. J., Litman, T., Jønson, L., Hagedorn, P., Krejsgaard, T., Gniadecki, R., et al. (2013) · Cell Cycle · doi:10.4161/cc.24987 · Cited by 147
MicroRNA expression in Sézary syndrome: identification, function, and diagnostic potential
Ballabio, E., Mitchell, T. J., van Kester, M. S., Taylor, S., Dunlop, H. M., Chi, J., Tosi, I., Vermeer, M. H., Tramonti, D., Saunders, N. J. S. G., et al. (2010) · Blood · doi:10.1182/blood-2009-12-256719 · Cited by 139
NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia
Gerloff, D., Grundler, R., Wurm, A. A., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Madan, V, Müller-Tidow, C., Duyster, J., Tenen, D. G., et al. (2015) · Leukemia · doi:10.1038/leu.2014.231 · Cited by 135
Huang, X., Shen, Y., Liu, M., Bi, C., Jiang, C., Iqbal, J., McKeithan, T. W., Chan, W. C., Ding, S., & Fu, K. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.013 · Cited by 134
Narducci, M. G., Arcelli, D., Picchio, M. C., Lazzeri, C., Pagani, E., Sampogna, F., Scala, E., Fadda, P., Cristofoletti, C., Facchiano, A., et al. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.32 · Cited by 131
Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells
Babar, I., Czochor, J. R., Steinmetz, A., Weidhaas, J. B., Glazer, P. M., & Slack, F. J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.10.17681 · Cited by 129
Shin, J. J., Monti, S., Aires, D., Duvic, M. A., Golub, T. R., Jones, D. A., & Kupper, T. S. (2007) · Blood · doi:10.1182/blood-2006-12-061507 · Cited by 129
Self-citationIzban, K. F., Ergin, M., Qin, J. Z., Martinez, R. L., RJ, J. R. P., Saeed, S., & Alkan, S. (2000) · Human Pathology · doi:10.1053/hupa.2000.20370 · Cited by 123
Signal transduction by MAP kinases in T lymphocytes
Rincón, M., Flavell, R. A., & Davis, R. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204382 · Cited by 122
Norfo, R., Zini, R., Pennucci, V., Bianchi, E., Salati, S., Guglielmelli, P., Bogani, C., Fanelli, T., Mannarelli, C., Rosti, V., et al. (2014) · Blood · doi:10.1182/blood-2013-12-544197 · Cited by 120
Qin, J., Zhang, C., Kamarashev, J. A., Dummer, R., Burg, G., & Döbbeling, U. (2001) · Blood · doi:10.1182/blood.v98.9.2778 · Cited by 114
MicroRNA-155 Promotes Atherosclerosis Inflammation via Targeting SOCS1
Yang, Y., Yang, L., Liang, X., & Zhu, G. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430303 · Cited by 106
miRNA expression profiling of mycosis fungoides
van Kester, M. S., Ballabio, E., Benner, M. F., Chen, X. H., Saunders, N. J. S. G., van der Fits, L., van Doorn, R., Vermeer, M. H., Willemze, R., Tensen, C. P., et al. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.02.003 · Cited by 100
Litvinov, I. V., Tetzlaff, M. T., Thibault, P., Gangar, P., Moreau, L., Watters, A. K., Netchiporouk, E., Pehr, K., Prieto, V. G., Rahme, E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1306618 · Cited by 100
Self-citationvan Kester, M. S., Borg, M. K., Zoutman, W. H., Out‐Luiting, J. J., Jansen, P. M., Dreef, E. J., Vermeer, M. H., van Doorn, R., Willemze, R., & Tensen, C. P. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.117 · Cited by 86
Sandoval, J., Díaz‐Lagares, Á., Salgado, R., Servitje, O., Climent, F., Ortiz-Romero, P. L., Pérez‐Ferriols, A., García-Muret, M. P., Estrach, T., Garcia, M., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.487 · Cited by 85
Litvinov, I. V., Netchiporouk, E., Cordeiro, B., Doré, M.-A., Moreau, L., Pehr, K., Gilbert, M. J., Zhou, Y., Sasseville, D., & Kupper, T. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3322 · Cited by 83
Litvinov, I. V., Cordeiro, B., Fredholm, S., Ødum, N., Zargham, H., Huang, Y., Zhou, Y., Pehr, K., Kupper, T. S., Woetmann, A., et al. (2014) · Cell Cycle · doi:10.4161/15384101.2014.947759 · Cited by 78
Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma
Litvinov, I. V., Jones, D. A., Sasseville, D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2879 · Cited by 78
Ralfkiær, U., Lindahl, L. M., Lindal, L., Litman, T., Gjerdrum, L. M. R., Ahler, C. B., Gniadecki, R., Marstrand, T. T., Fredholm, S., Iversen, L., et al. (2014) · PubMed · Cited by 74
Rasmussen, T. K., Andersen, T., Bak, R. O., Yiu, G., Sørensen, C. M., Stengaard‐Pedersen, K., Mikkelsen, J. G., Utz, P. J., Holm, C. K., & Deleuran, B. W. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0660-z · Cited by 64
Janssen, H. L. A., Kauppinen, S., & Hodges, M. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1307787 · Cited by 63
Netchiporouk, E., Gantchev, J. K., Tsang, M., Thibault, P., Watters, A. K., Hughes, J.-D. M., Ghazawi, F. M., Woetmann, A., Ødum, N., Sasseville, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21619 · Cited by 61
Discovery and Development of Small Molecule SHIP Phosphatase Modulators
Viernes, D. R., Choi, L. B., Kerr, W. G., & Chisholm, J. D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21305 · Cited by 60
Lessons learned from gene expression profiling of cutaneous T-cell lymphoma
Dulmage, B., & Geskin, L. J. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12578 · Cited by 55
miR‐155 is involved in tumor progression of mycosis fungoides
Moyal, L., Barzilai, A., Gorovitz, B., Hirshberg, A., Amariglio, N., Jacob‐Hirsch, J., Maron, L., Feinmesser, M., & Hodak, E. (2013) · Experimental Dermatology · doi:10.1111/exd.12161 · Cited by 47
Altered microRNA expression in mycosis fungoides
Maj, J., Jankowska‐Konsur, A., Sadakierska−Chudy, A., Noga, L., & Reich, A. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10669.x · Cited by 34
Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas
Marstrand, T. T., Ahler, C. B., Ralfkiær, U., Clemmensen, A., Kopp, K., Sibbesen, N. A., Krejsgaard, T., Litman, T., Wasik, M. A., Bonefeld, C. M., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.815352 · Cited by 33
Expression of miR‐155 and miR‐126 in situ in cutaneous T‐cell lymphoma
Kopp, K., Ralfkiær, U., Nielsen, B. S., Gniadecki, R., Woetmann, A., Ødum, N., & Ralfkiaer, E. M. (2013) · Apmis · doi:10.1111/apm.12162 · Cited by 29
Tracey, L., Spiteri, I., Ortiz-Romero, P. L., Lawler, M., Piris, M. A., & Villuendas, R. (2004) · Journal of Interferon & Cytokine Research · doi:10.1089/107999004322917034 · Cited by 26
Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides
Garaicoa, F. H., Roisman, A., Arias, M., Trila, C., Fridmanis, M., Abeldaño, A. M., Vanzulli, S. I., Narbaitz, M., & Slavutsky, I. R. (2016) · Tumor Biology · doi:10.1007/s13277-016-5259-8 · Cited by 18
Novel treatment options for the management of heterozygous familial hypercholesterolemia
Polychronopoulos, G., & Τζιόμαλος, Κ. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1378096 · Cited by 16
Yang, B., Yu, D., Liu, J., Yang, K., Wu, G., & Liu, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-3156-1 · Cited by 15
Evolution of the Mir-155 Family and Possible Targets in Cancers and the Immune System
Xie, G.-B., Liu, W., Pan, Z., Cheng, T., & Luo, C. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.18.7547 · Cited by 9
Cited by
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
MicroRNA-Based Diagnosis and Therapy
Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137167 · Cited by 630
Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., & Hahne, J. C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00717-x · Cited by 606
Metadata
- Authors
- Seto, A. G., Beatty, X., Lynch, J. M., Hermreck, M., Tetzlaff, M., Duvic, M., & Jackson, A. L.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2018-08-20
- Volume
- 183
- Issue
- 3
- Pages
- 428-444
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2888531381
- Cited by
- 333
- References
- 67
- FWCI
- 26.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.